Aragen has begun producing Renaissance Pharma's mAb, a drug in fast-track status by the FDA, after completing a nine-month technology transfer process.
Aragen Biopharma has commenced manufacturing of Renaissance Pharma’s monoclonal antibody (mAb), which is currently under Fast Track designation from the U.S. Food and Drug Administration (FDA). This development follows an intensive 9-month technology transfer period that enabled Aragen to scale up production of Daretabart, a key component in this mAb.
The successful completion of the technology transfer process marks a significant milestone for both companies as they move closer to bringing this promising therapeutic to market. The Fast Track designation by the FDA underscores the potential clinical importance and urgency of the drug’s development, highlighting its significance in addressing unmet medical needs.
Aragen Biopharma has demonstrated its capability to handle complex biologics manufacturing through this collaboration with Renaissance Pharma. The rapid scaling up from a technology transfer phase to commercial-ready production within nine months showcases Aragen's expertise and commitment to supporting innovative pharmaceutical projects.
This partnership between Aragen and Renaissance Pharma is expected to accelerate the timeline for bringing Daretabart to patients who may benefit from its potential therapeutic benefits, thereby addressing critical health needs in a timely manner.
